已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial

阿利罗库单抗 医学 他汀类 内科学 危险系数 PCSK9 急性冠脉综合征 不利影响 安慰剂 心肌梗塞 心脏病学 胆固醇 置信区间 脂蛋白 低密度脂蛋白受体 替代医学 病理 载脂蛋白A1
作者
Rafael Díaz,Qian H Li,Deepak L. Bhatt,Vera Bittner,Marie T. Baccara‐Dinet,Shaun G. Goodman,J. Wouter Jukema,Takeshi Kimura,Alexander Parkhomenko,Robert Pordy,Željko Reiner,Matthew W. Sherwood,Michael Szarek,Hung‐Fat Tse,Harvey D. White,Doron Zahger,Andreas M. Zeiher,Gregory G. Schwartz,Philippe Gabríel Steg
出处
期刊:European Journal of Preventive Cardiology [Oxford University Press]
卷期号:28 (1): 33-43 被引量:43
标识
DOI:10.1177/2047487320941987
摘要

Abstract Aims Statins are pivotal to the secondary prevention of major adverse cardiovascular events, but some patients are statin-intolerant. We examined the effects of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab on the risk of major adverse cardiovascular events according to the intensity of background statin treatment. Methods and results The ODYSSEY OUTCOMES trial compared alirocumab with placebo in 18,924 patients with acute coronary syndrome and dyslipidaemia despite intensive or maximum-tolerated statin treatment (including no statin if intolerance was documented). The primary outcome (major adverse cardiovascular events) comprised coronary heart disease death, non-fatal myocardial infarction, ischaemic stroke, or unstable angina. Median follow-up was 2.8 years. Baseline statin treatment was high-intensity (88.8%), low/moderate-intensity (8.7%) or none (2.4%). Median baseline low-density lipoprotein cholesterol was 86, 89 and 139 mg/dL (P < 0.001) in these statin treatment categories, respectively. Alirocumab produced similar relative reductions in low-density lipoprotein cholesterol from baseline across statin treatment subgroups, but the mean absolute reductions differed (52.9, 56.7 and 86.1 mg/dL, respectively; P < 0.001). With placebo, the incidence of major adverse cardiovascular events was highest in the no statin subgroup (10.8%, 10.7% and 26.0% respectively). Alirocumab reduced major adverse cardiovascular events in each statin subgroup (hazard ratio 0.88, 95% confidence interval (CI) 0.80–0.96; 0.68, 0.49–0.94; and 0.65, 0.44–0.97, respectively; Pinteraction = 0.14) with a gradient of absolute risk reduction: 1.25%, 95% CI 0.34–2.16; 3.16%, 0.38–5.94; 7.97%, 0.42–15.51; Pinteraction = 0.106). Conclusions PCSK9 inhibition with alirocumab reduces the relative risk of major adverse cardiovascular events after acute coronary syndrome irrespective of background statin treatment. However, patients on no statin are at high absolute risk for recurrent major adverse cardiovascular events; alirocumab substantially reduces that risk. PCSK9 inhibition may be an important therapeutic strategy for statin-intolerant patients with acute coronary syndrome.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
JJ完成签到,获得积分10
刚刚
芯之痕发布了新的文献求助10
2秒前
Trends发布了新的文献求助10
2秒前
hhhhhhhhhh完成签到 ,获得积分10
4秒前
鱼生完成签到,获得积分10
7秒前
李世航完成签到,获得积分10
7秒前
xixi完成签到 ,获得积分10
7秒前
swimming完成签到 ,获得积分10
7秒前
9秒前
果冻橙发布了新的文献求助10
13秒前
sjw发布了新的文献求助10
15秒前
wenlong完成签到 ,获得积分10
15秒前
15秒前
无花果应助Naturewoman采纳,获得10
16秒前
简单的季风完成签到 ,获得积分20
17秒前
无限的书芹完成签到 ,获得积分10
17秒前
19秒前
CR7应助咸鱼王采纳,获得20
20秒前
zzf完成签到,获得积分10
20秒前
suiyi发布了新的文献求助10
20秒前
22秒前
Tim完成签到 ,获得积分10
22秒前
23秒前
serendipity完成签到 ,获得积分10
24秒前
优秀黑夜发布了新的文献求助10
25秒前
26秒前
yatuitui完成签到,获得积分10
26秒前
小马甲应助椒盐鲨鱼皮采纳,获得10
26秒前
木讷山发布了新的文献求助10
28秒前
HTniconico完成签到 ,获得积分10
29秒前
活泼的草莓完成签到,获得积分10
31秒前
Naturewoman发布了新的文献求助10
32秒前
32秒前
情怀应助活泼的草莓采纳,获得10
35秒前
优雅雅绿完成签到 ,获得积分10
35秒前
张先生完成签到 ,获得积分10
36秒前
量子星尘发布了新的文献求助10
38秒前
cyy发布了新的文献求助10
38秒前
vin发布了新的文献求助50
39秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976572
求助须知:如何正确求助?哪些是违规求助? 3520659
关于积分的说明 11204365
捐赠科研通 3257284
什么是DOI,文献DOI怎么找? 1798667
邀请新用户注册赠送积分活动 877835
科研通“疑难数据库(出版商)”最低求助积分说明 806577